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Prosthetic joints and other orthopaedic implants have improved quality of life for patients 
world-wide and the use of such devices is increasing. However, while infection rates 
subsequent to associated surgery are relatively low (<3%), the consequences of incidence 
are considerable, encompassing morbidity (including amputation) and mortality in 
addition to significant social and economic costs.  Emphasis, therefore, has been placed 
on mitigating microbial risk, with clinical microbiologists and surgeons utilizing rapidly 
evolving molecular laboratory techniques in detection and diagnosis of infection, which 
still occurs despite sophisticated patient management. Multidisciplinary approaches are 
regularly adopted to achieve this. In this commentary, we describe an unusual case of 
Actinomyces infection in total hip arthroplasty and, in that context, describe the 
perspectives of the clinical microbiology and surgical teams and how they contrasted. 
More specifically, this case demonstrates an ad hoc approach to structured eradication of 
biofilms and intracellular bacteria related to biomaterials, as reflected in early usage of 
linezolid. This is a complex topic as, and as described in this case, such accelerated 
treatment can be effective. This commentary focuses on the merits of such inadvisable 
use of potent antimicrobials amid the risk of diminishing valuable antimicrobial efficacy, 
albeit resulting in desirable patient outcomes. 
 
Introduction 
North America has experienced significant declines in mortality secondary to infectious 
diseases.1 In the European Union, incidence of severe sepsis, associated with multiorgan 
failure, is currently estimated as 90.4 cases per 100,000 population.2 Not least, in 
bringing about improvements, have been the adoption of enhanced infection control 
practices, efficacious antimicrobial therapies, advanced molecular-based laboratory 
methodologies and sepsis management protocols.3 Indeed, direct links have been 
demonstrated between time required for pathogen identification and infectious illness 
outcomes.4 In response, use of molecular-based laboratory technologies has become more 
common, leading to more rapid microbial identification, susceptibility testing, reduction 
in empiric antimicrobial use, faster application of targeted therapies and, overall, 
enhanced patient care. 5 
Despite these advances, surgical practice can require decision-making with respect to 
treatment of nosocomial or procedure-related infections, often in the absence of 
laboratory data regarding the nature of causative organisms, whether those infections are 
monomicrobial or polymicrobial, and their relative sensitivities to available bacteriostatic 
or bacteriocidal agents. There is, therefore, an imperative that clinical and molecular 
microbiologists determine accurate etiological diagnoses enabling selection of the most 
appropriate antimicrobial treatments. However, while laboratory analysis is underway, 
surgical teams may decide to engage in broad spectrum empiric treatments, using 
parenteral or oral therapy, as well as consideration of further surgical management. 
In the case of orthopaedic surgery, specifically, the use of prosthetic joints and other 
implants has been associated with relatively low levels of infection (<3%).6 Focusing 
more keenly on total hip arthroplasty, or hip replacement, reports of infection classify 
occurence based on the timing of incidence: “early” within one month of procedure, 
“delayed” within a year, and “late” at any time after that.7 8 Such infections are 
considered a serious complication9, with “early” and “delayed” infection typically due to 
perioperative bacterial contamination, whereas “late” incidence is understood to be 
predominantly blood-borne.7 10  
 
The Case  
Prosthetic joint infections typically result from monomicrobial contamination by 
Staphylococcus aureus or S. epidermis, with much fewer cases associated with any other 
species.11 12 13 14 15 In this case, a 71 year old man had presented 9 years following hip 
arthroplasty with hip pain and elevated inflammatory markers (erythrocyte sedimentation 
rate of 71 mm/h and c-reactive protein of 65 mg/l).7 Imaging techniques indicated that 
there was evidence of osteolysis, subsequent biopsies of adjacent tissue confirmed 
presence of Actinomyces israelii. Treatment involved removal of the prosthesis, insertion 
of vancomycin-loaded bone cement spacer, intravenous antimicrobials, and eventual re-
implantation with a new prosthesis. There has been no recurrence of infection to date. 
 
The Microbiologist Perspective 
Actinomyces israelii is a filamentous Gram-positive anaerobic bacterium, is considered 
only opportunistically pathogenic,16 and is frequently isolated from the gastrointestinal 
tract, bronchi, oral cavities and female genital tract.14 17 Pathogenesis most commonly 
involves dental caries or gingival disease, with infections of the lung or abdomen being 
the next most common. A. israelii infection in hip replacement is extremely rare with 
only 3 previous reported cases in the literature, associated with contamination at the time 
of surgery13, dental work without antibiotic prophylaxis14, and intravenous drug abuse17. 
In the present case, infection occurred with Type 2 diabetes mellitus the dominant risk 
factor.  
For the reasons outlined above, Actinomyces infection was not initially suspected in this 
case. Indeed, aspirate from the painful hip joint was devoid of microbes (Figure 1) and it 
was only following culture of biopsies from periprosthetic tissue that A. israelii was 
detected. The microbiological process (Figure 1) involved 10 days anaerobic incubation 
on blood agar and use of biochemical kits (bioMérieux®API®). Laboratory assays 
demonstrated susceptibility to penicillin, teicoplanin, vancomycin, ciprofloxacin and 
linezolid. These results corresponded broadly with expert recommendations for 
antimicrobial therapy18 19 including prolonged high does of parenteral penicillin, 
followed by oral penicillin / amoxicillin or tetracyclin, erythromycin, doxycycline or 
clindamycin if penicillin is not an option.20 
 
The Surgeon Perspective 
An empirical antimicrobial approach was adopted (Figure 2). A vancomycin-loaded 
cement spacer was put in place and intravenous teicoplanin administered until the 
infectious agent was identified and susceptibility to vancomycin was confirmed by the 
clinical microbiology team, at which point teicoplanin was discontinued. The subsequent 
therapeutic approach deviated from recommended anti-actinomycosis protocols,20 
through relatively long-term (28 day) use of linezolid, due to the following factors:  
• Requirement for eradication of infection before any re-implantation could occur 
• Recognition that biofilm formation, initially associated with the pathogenesis of 
catheter-related infection but now considered a key aspect of many biomaterial-
related microbes, may be involved. 21 This was potentially indicated by the lack of 
recoverable bacteria from the aspirated synovial fluid. 
• Linezolid has demonstrated efficacy against most Gram-positive pathogens, 
including multidrug-resistant staphylococci.22 23  
• Linezolid has been shown to accumulate rapidly in bone, with reported efficacy in 
a broad range of orthopaedic infections.24  
 
Discussion 
Amongst the primary roles of the clinical microbiologist are guidance and support of 
surgical teams, and selection of appropriate diagnostic investigations and antimicrobials, 
as warranted.5 In this case, the recommended antibiotic treatment profile, based on 
susceptibility testing, included teicoplanin and vancomycin. However, the imperative for 
the surgical team was eradication of Actinomyces associated with bone prosthesis. In that 
context, linezolid was a suitable antimicrobial due to its proven ability to achieve high 
concentrations in bone,24 and so the patient was administered a four week oral course (2x 
600 mg day-1). 
From a clinical microbiologist perspective, this course of treatment would be undesirable 
as linezolid is generally reserved for treatment of multidrug-resistant microbes. 
Worryingly, although resistance to linezolid is difficult to generate in vitro,23 emergence 
of cfr-related in vivo resistance has been reported25 26 27 in addition to only bacteriostatic 
activity against staphylococci and Enterococcus spp.28 Indeed, pharmacodynamic studies 
provide evidence of low AUC24/MIC related to high numbers of therapeutic failure,28 
including orthopaedic applications.29 30 Of even greater concern to the clinical 
microbiologist, however, are reports of adverse events associated with relatively long-
term use of linezolid,31 32 analogous to the four week regimen in this case (although 
linezolid is approved for treatment of that duration).  
The surgeon-led patient-centred care commented on here focused on efficacy of 
treatment appropriate to an elderly man. Since approximately 1996, management of 
similar cases have employed both two-stage surgery (i.e., removal of infected prostheses 
– sometimes use of antibiotic-loaded spacers – eradication of causative pathogens 
followed by replacement of devices) and intracellular antimicrobials to avoid relapse due 
to potential harbouring of bacteria within periprosthetic fibroblasts.33 That was the 
approach adopted in this case, oral linezolid facilitating outpatient-based treatment and, 
importantly for the elderly patient, markedly reduced discomfort for him and his family. 
In conclusion, advances in molecular technologies for rapid species identification and 
susceptibility testing are mitigating the protracted incubation times associated with 
conventional microbiology, facilitating quicker diagnosis and reduction in exposure of 
patients to empiric therapy in favour of targeted antimicrobial use. In the specific case 
described here, the use of the linezolid proved successful, with no adverse events evident. 
However, it is probable that double-blind, randomized trials of linezolid in orthopaedic 
settings are necessary to clarify its efficacy and, therefore, suitability for use.  
 Figure	  1	   X-­‐ray	   showing	   translucency	   surrounding	   the	   femoral	   component	   of	  the	   prosthesis.	   Aspirate	   was	   negative	   for	   infection.	   Subsequent	   analysis	   of	   the	  acetobulum	  proved	  positive	  for	  Actinomyces	  Israelii.	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